Reports

Ideas That Generate Results

List of Figures:

Figure 4-1: Relation between Country Income and Under-5 Child Deaths from Pneumonia
Figure 4-2: Impact of Childhood Conjugate Pneumococcal Immunization on Incidence of Disease in < 5 Years of Age
Figure 4-3: Herd Immunity Impact of Childhood Pneumococcal Immunization in the US
Figure 4-4: Pneumonia Vaccine Market (Million US$), 2009-2014
Figure 4-5: Pneumonia Vaccine Market (Million Doses), 2009-2014
Figure 4-6: Pneumonia Vaccine Market (Million US$), 2014-2020
Figure 4-7: Pneumococcal Vaccine Market by Geography (%), 2014
Figure 4-8: Percentage of Adults Aged 65 and over who had ever received a Pneumococcal Vaccination: United States, 1997-2013
Figure 4-9: Age-Adjusted Death Rates for Pneumonia in 2013: United States, 1999-2013
Figure 6-1: Pneumococcal Vaccine Market Value Share by Players (%), 2014
Figure 6-2: Pneumococcal Vaccine Market Volume Share by Players (%), 2014
Figure 6-3: GSK - Revenue by Geographic Segment (%), 2014
Figure 6-4: GSK - Revenue by Business Segment (%), 2014
Figure 6-5: GSK - Break-up of Revenue of Pharmaceutical and Vaccines Business Segment (%), 2014
Figure 6-6: GSK - Synflorix Sales (Million GBP), 2010-2014
Figure 6-7: Pfizer - Revenue by Geography (%), 2014
Figure 6-8: Pfizer - Revenue by Business Segment (%), 2014
Figure 6-9: Pfizer - Prevnar Family Sales (Million USD), 2010-2014
Figure 6-10: Merck - Revenue by Business Segment (%), 2014
Figure 6-11: Merck - Revenue by Geography (%), 2014
Figure 6-12: Merck - Pneumovax 23 Sales (Million USD), 2010-2014

List of Tables:

Table 4-1: Current levels of coverage for interventions that prevent (vaccination) Pneumonia
Table 6-1: GSK - Pneumonia Vaccine Portfolio
Table 6-2: GSK - Key Financials (Million GBP), 2012-2014
Table 6-3: GSK - Strengths and Weaknesses
Table 6-4: Pfizer - Pneumonia Vaccine Portfolio
Table 6-5: Pfizer - Key Financials (Million US$), 2012-2014
Table 6-6: Pfizer - Strengths and Weaknesses
Table 6-7: Merck - Pneumonia Vaccine Portfolio
Table 6-8: Merck - Key Financials (Millions US$), 2012-2014
Table 6-9: Merck - Strengths and Weaknesses